Takeda reports solid Q1 sales growth ahead of anticipated generic headwinds

27 Jul 2023
firstwordpharma.com
BiosimilarFinancial Statement
Headline results for the first fiscal quarter:
Revenue: JPY 1058.6 billion ($7.6 billion), up 8.9%
Net profit: JPY 89.4 billion ($63 million), down 14.9%
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
Chief financial officer Costa Saroukos noted that “our growth and launch products continued to drive revenue growth in the first quarter. While we still anticipate headwinds affecting our business this fiscal year, largely due to generic competition, we remain confident of a return to growth in the near-term.”
Notable patent expiries in 2023 include Takeda's blood pressure drug Azilva in Japan and its hyperactivity treatment Vyvanse in the US.
Other results:
Gastroenterology product sales: JPY 294 billion, up 8.6%
Entyvio: JPY 192 billion, up 14.1%
Gattex/Revestive: JPY 27.1 billion, up 23.6%
Takecab/Vocinti: JPY 29.8 billion, up 7.9%
Rare diseases product sales: JPY 192.6 billion, up 6.1%
Rare haematology product sales: JPY 81.4 billion, up 2.8%
Advate: JPY 33.8 billion, up 5.4%
Rare genetics product sales: JPY 111.3 billion, up 8.5%
Takhzyro: JPY 41.3 billion, up 21.4%
Plasma-derived therapy/immunology sales: JPY 186.5 billion, up 31.5%
Neuroscience product sales: JPY 177 billion, up 24.3%
Vyvanse/Elvanse: JPY 123.2 billion, up 23.2%
Oncology product sales: JPY 110.5 billion, down 6%
Adcetris: JPY 27.1 billion, up 35.8%
Velcade: JPY 1.8 billion, down 89%
Looking ahead:
Takeda said it expects eight key regulatory decisions to occur by the end of its 2023 financial year.
($1 = JPY 139.886)
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.